Video
TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemo
CHICAGO - Lead study author Dr. Joseph A. Sparano discusses the implications of the new data for decision-making and future plans for the tumor...
News
Atezolizumab has PFS benefit in first-line squamous NSCLC
CHICAGO – Atezolizumab prolongs PFS by about a month, and patients derived benefit regardless of the level of PD-L1 expression.
Video
A blood test to detect lung cancer inches toward the clinic
CHICAGO - Dr. Geoffrey R. Oxnard discusses interim results from the Circulating Cell-Free Genome Atlas project and ongoing work to bring the blood...
Video
Metastatic colorectal cancer chemo costs double in Washington vs. British Columbia
CHICAGO - Dr. Todd Yezefski discusses the drivers of cost disparities and implications for policy makers.
Video
Head and neck cancers: Women less commonly receive intensive chemo
CHICAGO - Senior study author Dr. Jed A. Katzel discusses ongoing research to understand the reasons behind the apparent disparities.
News
CBT-I bests acupuncture for treating insomnia among cancer survivors
In a randomized trial, both CBT-I and acupuncture reduced insomnia severity among cancer survivors, but the former had the edge.
News
Uptake of lung cancer screening is exceedingly low
The annual rate of LDCT screening for lung cancer among eligible current and former heavy smokers was just 1.9% in 2016 across the United States...
News
New remote monitoring system lessens symptoms in head and neck cancer
The CYCORE system, which harnesses wireless sensor and mobile technology to remotely monitor vitals and symptoms, reduces symptom severity in...
News
Adjuvant trastuzumab for breast cancer: 6 months may suffice
Disease-free survival was similarly high whether women received adjuvant trastuzumab for the current standard of 12 months or for just 6 months....
News
New regimens for youth with T-cell malignancies yield best outcomes yet
More than 8 in 10 youth were still alive and free of disease 4 years after starting combinations of methotrexate and/or nelarabine with chemo.
News
Upfront NGS testing of metastatic NSCLC saves money, time
NGS at the time of metastatic NSCLC diagnosis could save millions of dollars relative to more conservative testing strategies, and results become...
News
Emerging data help inform immunotherapy for urothelial cancer
Atezolizumab had a marked survival benefit vs. chemotherapy in patients with TMB-high, PD-L1–positive urothelial tumors.
News
New treatment options emerge for intermediate, advanced HCC
SAN FRANCISCO – Two new therapies that target VEGF signaling are efficacious and may expand the treatment for intermediate and advanced HCC.
News
Enzalutamide shines in nonmetastatic castration-resistant prostate cancer
SAN FRANCISCO - Metastasis-free survival was 36.6 months with enzalutamide and 14.7 months with placebo.
News
Bladder cancer: Two chemoradiation therapy regimens on par for muscle-invasive disease
Primary results were comparable in the NRG/RTOG 0712 trial, but one regimen is more convenient.